Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 2
2005 2
2006 3
2007 3
2008 3
2009 1
2010 7
2011 6
2012 7
2013 10
2014 17
2015 23
2016 9
2017 8
2018 10
2019 8
2020 14
2021 19
2022 10
2023 6
2024 9
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Large clones of Clonal Hematopoiesis affect outcome in Mantle Cell Lymphoma: Results from The FIL MCL0208 Clinical Trial.
Ragaini S, Galli A, Genuardi E, Gandossini M, Alessandria B, Civita AM, Evangelista A, Amaducci E, Stefoni V Dr, Cavallo F, Ballerini F, Puccini B, Vallisa D, Michieli M, Pascarella A, Palmas AD, Patti C, Lucchini E, Careddu MG, Merli M, Postorino M, Boccomini C, Balzarotti M MD, Zilioli VRR, da Silva MG, Bruno B, Rizzo E, Ladetto M, Malcovati L, Ferrero S. Ragaini S, et al. Among authors: ladetto m. Blood Adv. 2025 Jan 14:bloodadvances.2024014948. doi: 10.1182/bloodadvances.2024014948. Online ahead of print. Blood Adv. 2025. PMID: 39808795
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial.
Clerico M, Ferrero S, Alessandria B, Zaccaria GM, Genuardi E, Ragaini S, Tavarozzi R, Cavallo F, Hohaus S, Musuraca G, Carella AM, Stelitano C, Tani M, Gaidano G, Olivieri J, Usai SV, Galimberti S, Re F, Mian M, Castellino C, Pavone V, Evangelista A, Bruno B, Cortelazzo S, Passera R, Ladetto M. Clerico M, et al. Among authors: ladetto m. Sci Rep. 2024 Jul 23;14(1):16946. doi: 10.1038/s41598-024-67906-w. Sci Rep. 2024. PMID: 39043871 Free PMC article. Clinical Trial.
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Carrabba MG, Cutini I, Martino M, Dodero A, Bonifazi F, Santoro A, Sorà F, Botto B, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Ladetto M, Cavallo F, Massaia M, Arcaini L, Pennisi M, Zinzani PL, Miceli R, Corradini P. Stella F, et al. Among authors: ladetto m. Blood Cancer Discov. 2024 Sep 3;5(5):318-330. doi: 10.1158/2643-3230.BCD-24-0052. Blood Cancer Discov. 2024. PMID: 38953781 Free PMC article.
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial.
Pulsoni A, Ferrero S, Tosti ME, Luminari S, Dondi A, Cavallo F, Merli F, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJM, Rattotti S, Zilioli VR, Bolis SA, Bernuzzi P, Musuraca G, Gaidano G, Perrone T, Stelitano C, Tucci A, Corradini P, Bigliardi S, Re F, Cencini E, Mannarella C, Mannina D, Celli M, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Bomben R, Ciabatti E, Genuardi E, Drandi D, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. Pulsoni A, et al. Among authors: ladetto m. Lancet Haematol. 2024 Jul;11(7):e499-e509. doi: 10.1016/S2352-3026(24)00143-1. Lancet Haematol. 2024. PMID: 38937025 Clinical Trial.
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, Peano S, Franceschetto A, Monaco L, Barbieri E, Ladetto M, Musuraca G, Tosi P, Bianchi B, Bolis SAM, Pavone V, Chiarenza A, Arcari A, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Roti G, Galimberti S, Gini G, Falcinelli F, Vitolo U, Usai SV, Stefani PM, Ibatici A, Liberati AM, Pennese E, Perrone T, Versari A, Luminari S; Fondazione Italiana Linfomi (FIL). Guerra L, et al. Among authors: ladetto m. Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 May 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120 Clinical Trial.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote V, Shpilberg O, Gomes da Silva M, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Celli M, Hess G, Arcaini L, Visco C, van Meerten T, Wirths S, Zinzani PL, Novak U, Herhaus P, Benedetti F, Sonnevi K, Hanoun C, Hänel M, Dierlamm J, Pott C, Klapper W, Gözel D, Schmidt C, Unterhalt M, Ladetto M, Hoster E. Dreyling M, et al. Among authors: ladetto m. Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2. Lancet. 2024. PMID: 38705160 Free article. Clinical Trial.
Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Niederwieser C, Iacobelli S, Franke GN, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LP, Stelljes M, Morozova E, Passweg J, Onida F, Dreger P, Saccardi R, Ladetto M, Salmenniemi U, Bethge W, Poiré X, Kobbe G, McLornan DP, Robin M, Kröger N. Niederwieser C, et al. Among authors: ladetto m. Bone Marrow Transplant. 2024 Aug;59(8):1084-1091. doi: 10.1038/s41409-024-02282-7. Epub 2024 Apr 25. Bone Marrow Transplant. 2024. PMID: 38664589 Free PMC article. Clinical Trial.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K, Carras S, Gini G, Camus V, Mancuso S, Marcheselli L, Ferrari A, Merli M, Tessoulin B, Stelitano C, Beldjord K, Roti G, Jardin F, Castagnari B, Palombi F, Baseggio L, Traverse-Glehen A, Tripodo C, Liberati AM, Parolini M, Usai S, Patti C, Federico M, Musso M, Ladetto M, Zucca E, Thieblemont C. Iannitto E, et al. Among authors: ladetto m. Haematologica. 2024 Jul 1;109(7):2297-2302. doi: 10.3324/haematol.2023.284109. Haematologica. 2024. PMID: 38497158 Free PMC article. Clinical Trial. No abstract available.
164 results